MedTrace Logo

Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors

NCT04052204 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2021-10-14

Study results available
· View outcomes & findings →

Summary

Evaluation of the combination of avelumab + bempegaldesleukin (NKTR-214 ) in locally advanced squamous cell carcinoma of the head and neck ( metastatic SCCHN) and avelumab + bempegaldesleukin (NKTR-214) + talazoparib or enzalutamide in metastatic castration resistant prostate cancer (mCRPC).

Conditions

  • Squamous Cell Carcinoma of the Head and Neck (SCCHN)
  • Metastatic Castration Resistant Prostate Cancer (mCRPC)

Interventions

DRUG

avelumab

Investigational fully human anti-PD-L1 monoclonal antibody

DRUG

Bempegaldesleukin

Investigational CD122-biased cytokine agonist

DRUG

talazoparib

poly (adenosine diphosphate \[ADP\] ribose) polymerase (PARP) inhibitor

DRUG

enzalutamide

androgen receptor inhibitor

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-30
Primary Completion
2020-09-29
Completion
2020-09-29
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Poland
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04052204 on ClinicalTrials.gov